Optimal cut-off value for identifying objective response in patients with nasopharyngeal carcinoma after induction chemotherapy

被引：1

作者：

Luo, Chao ^{[1
]}

Huang, Wenjie ^{[1
]}

Li, Shuqi ^{[1
]}

Li, Haojiang ^{[1
]}

Ruan, Guangying ^{[1
]}

Fu, Gui ^{[1
,3
]}

Liu, Lizhi ^{[1
,2
,3
]}

机构：

[1] Sun Yat Sen Univ, Guangdong Prov Clin Res Ctr Canc, Guangdong Key Lab Nasopharyngeal Carcinoma Diag &, Canc Ctr,Dept Radiol,State Key Lab Oncol South Chi, Guangzhou, Peoples R China

[2] Third Peoples Hosp Shenzhen, Dept Radiol, Shenzhen, Peoples R China

[3] Sun Yat sen Univ, Guangdong Key Lab Nasopharyngeal Carcinoma Diag &, Dept Radiol, Canc Ctr,State Key Lab Oncol South China,Collabora, 651 Dongfeng Rd East, Guangzhou 510060, Guangdong, Peoples R China

来源：

HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK | 2024年 / 46卷 / 10期

基金：

中国国家自然科学基金;

关键词：

induction chemotherapy; magnetic resonance imaging; nasopharyngeal carcinoma; prognosis; response evaluation criteria in solid tumors; THERAPY; SAFETY;

D O I：

10.1002/hed.27754

中图分类号：

R76 [耳鼻咽喉科学];

学科分类号：

100213 ;

摘要：

BackgroundWe aimed to establish the most suitable threshold for objective response (OR) in the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 in patients with nasopharyngeal carcinoma (NPC).MethodsAccording to RECIST 1.1, we retrospectively evaluated MR images of NPC lesions in patients before and after induction chemotherapy (IC). Restricted cubic spline and maximally selected rank statistics were used to determine the cut-off value. Survival rates and differences between groups were compared with Kaplan-Meier curves and log-rank tests.ResultsOf 1126 patients, 365 cases who received IC treatment were suitable for RECIST 1.1 evaluation. The 20% cut-off value maximized between-group differences according to maximally selected rank statistics. No difference in distant metastasis-free survival between OR and non-response groups was shown using the primary threshold of OR (30%), while it differed when 20% was employed.ConclusionsWith an optimal cut-off value of 20%, RECIST may assist clinicians to accurately evaluate disease response in NPC patients.

引用

页码：2540 / 2549

页数：10

共 30 条

[1] Chemotherapy and radiotherapy in nasopharyngeal carcinoma: an update of the MAC-NPC meta-analysis [J].

Blanchard, Pierre ;

Lee, Anne ;

Marguet, Sophie ;

Leclercq, Julie ;

Ng, Wai Tong ;

Ma, Jun ;

Chan, Anthony T. C. ;

Huang, Pei-Yu ;

Benhamou, Ellen ;

Zhu, Guopei ;

Chua, Daniel T. T. ;

Chen, Yong ;

Mai, Hai-Qiang ;

Kwong, Dora L. W. ;

Cheah, Shie Lee ;

Moon, James ;

Tung, Yuk ;

Chi, Kwan-Hwa ;

Fountzilas, George ;

Zhang, Li ;

Hui, Edwin Pun ;

Lu, Tai-Xiang ;

Bourhis, Jean ;

Pignon, Jean Pierre .

LANCET ONCOLOGY, 2015, 16 (06) :645-655

[2] Unidimensional measurement may be superior to assess primary tumor response after neoadjuvant chemotherapy for nasopharyngeal carcinoma [J].

Chen, Chuanben ;

Lin, Xiurong ;

Xu, Yuanji ;

Bai, Penggang ;

Xiao, Youping ;

Pan, Yuhui ;

Li, Chao ;

Lin, Zhizhong ;

Zhang, Mingwei ;

Chen, Yunbin .

ONCOTARGET, 2017, 8 (29) :46937-46945

[3] Chemotherapy in Combination With Radiotherapy for Definitive-Intent Treatment of Stage II-IVA Nasopharyngeal Carcinoma: CSCO and ASCO Guideline [J].

Chen, Yu-Pei ;

Ismaila, Nofisat ;

Chua, Melvin L. K. ;

Colevas, A. Dimitrios ;

Haddad, Robert ;

Huang, Shao Hui ;

Wee, Joseph T. S. ;

Whitley, Alexander C. ;

Yi, Jun-Lin ;

Yom, Sue S. ;

Chan, Anthony T. C. ;

Hu, Chao-Su ;

Lang, Jin-Yi ;

Le, Quynh-Thu ;

Lee, Anne W. M. ;

Lee, Nancy ;

Lin, Jin-Ching ;

Ma, Brigette ;

Morgan, Thomas J. ;

Shah, Jatin ;

Sun, Ying ;

Ma, Jun .

JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (07) :840-+

[4] Nasopharyngeal carcinoma [J].

Chen, Yu-Pei ;

Chan, Anthony T. C. ;

Quynh-Thu Le ;

Blanchard, Pierre ;

Sun, Ying ;

Ma, Jun .

LANCET, 2019, 394 (10192) :64-80

[5] Induction Chemotherapy plus Concurrent Chemoradiotherapy in Endemic Nasopharyngeal Carcinoma: Individual Patient Data Pooled Analysis of Four Randomized Trials [J].

Chen, Yu-Pei ;

Tang, Ling-Long ;

Yang, Qi ;

Poh, Sharon-Shuxian ;

Hui, Edwin P. ;

Chan, Anthony T. C. ;

Ong, Whee-Sze ;

Tan, Terence ;

Wee, Joseph ;

Li, Wen-Fei ;

Chen, Lei ;

Ma, Brigette B. Y. ;

Tong, Macy ;

Tan, Sze-Huey ;

Cheah, Shie-Lee ;

Fong, Kam-Weng ;

Sommat, Kiattisa ;

Soong, Yoke Lim ;

Guo, Ying ;

Lin, Ai-Hua ;

Sun, Ying ;

Hong, Ming-Huang ;

Cao, Su-Mei ;

Chen, Ming-Yuan ;

Ma, Jun .

CLINICAL CANCER RESEARCH, 2018, 24 (08) :1824-1833

[6] New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) [J].

Eisenhauer, E. A. ;

Therasse, P. ;

Bogaerts, J. ;

Schwartz, L. H. ;

Sargent, D. ;

Ford, R. ;

Dancey, J. ;

Arbuck, S. ;

Gwyther, S. ;

Mooney, M. ;

Rubinstein, L. ;

Shankar, L. ;

Dodd, L. ;

Kaplan, R. ;

Lacombe, D. ;

Verweij, J. .

EUROPEAN JOURNAL OF CANCER, 2009, 45 (02) :228-247

[7] Twenty Years On: RECIST as a Biomarker of Response in Solid Tumours an EORTC Imaging Group - ESOI Joint Paper [J].

Fournier, Laure ;

de Geus-Oei, Lioe-Fee ;

Regge, Daniele ;

Oprea-Lager, Daniela-Elena ;

D'Anastasi, Melvin ;

Bidaut, Luc ;

Baeuerle, Tobias ;

Lopci, Egesta ;

Cappello, Giovanni ;

Lecouvet, Frederic ;

Mayerhoefer, Marius ;

Kunz, Wolfgang G. ;

Verhoeff, Joost J. C. ;

Caruso, Damiano ;

Smits, Marion ;

Hoffmann, Ralf-Thorsten ;

Gourtsoyianni, Sofia ;

Beets-Tan, Regina ;

Neri, Emanuele ;

deSouza, Nandita M. ;

Deroose, Christophe M. ;

Caramella, Caroline .

FRONTIERS IN ONCOLOGY, 2022, 11

[8] Comparison of CT volumetric measurement with RECIST response in patients with lung cancer [J].

Hayes, S. A. ;

Pietanza, M. C. ;

O'Driscoll, D. ;

Zheng, J. ;

Moskowitz, C. S. ;

Kris, M. G. ;

Ginsberg, M. S. .

EUROPEAN JOURNAL OF RADIOLOGY, 2016, 85 (03) :524-533

[9] Final results of a randomized phase III trial of induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in patients with stage IVA and IVB nasopharyngeal carcinoma-Taiwan Cooperative Oncology Group (TCOG) 1303 Study [J].

Hong, R. L. ;

Hsiao, C. F. ;

Ting, L. L. ;

Ko, J. Y. ;

Wang, C. W. ;

Chang, J. T. C. ;

Lou, P. J. ;

Wang, H. M. ;

Tsai, M. H. ;

Lai, S. C. ;

Liu, T. W. .

ANNALS OF ONCOLOGY, 2018, 29 (09) :1972-1979

[10] Safety and Antitumor Activity of Pembrolizumab in Patients With Programmed Death-Ligand 1-Positive Nasopharyngeal Carcinoma: Results of the KEYNOTE-028 Study [J].

Hsu, Chiun ;

Lee, Se-Hoon ;

Ejadi, Samuel ;

Even, Caroline ;

Cohen, Roger B. ;

Le Tourneau, Christophe ;

Mehnert, Janice M. ;

Algazi, Alain ;

van Brummelen, Emilie M. J. ;

Saraf, Sanatan ;

Thanigaimani, Pradeep ;

Cheng, Jonathan D. ;

Hansen, Aaron R. .

JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (36) :4050-+

← 1 2 3 →